The modification represents a greater reduction in dose intensity than the mFOLFIRINOX adopted by several Western groups. Encouraged by observed responses, we further evaluated the efficacy of mFOLFIRINOX in patients with LAPC with the goal of surgical resection in the event of an adequate response. Here, we enrolled patients with LAPC who underwent preoperative therapy with mFOLFIRINOX (LAPC-N) prospectively and compared the outcomes among patients with RPC or LAPC with upfront surgery (LAPC-S) whose data were collected retrospectively. mFOLFIRINOX was applied in 41 LAPC cases with an objective response rate of 37.1%, which was similar to that in published studies. In our cohort, 29.3% patients had grade 3 or 4 toxicities, with 10 (24.4%) suffering neutropenia and 9 (22.0%) having anemia. No severe fatigue, diarrhea, or vomiting was observed in our study. Our modification resulted in better tolerability without attenuating the efficacy of full-dose FOLFIRINOX.
Patients with LAPC benefited from tumor downstaging with mFOLFIRINOX-based NAT. Fourteen (34.1%) LAPC-N patients met the criteria for conversion to surgery after treatment (LAPC-N-S). According to histology, LAPC-S patients endured later stages of disease, and the incidence of lymph-node metastasis was much higher than that in the LAPC-N-S group. Moreover, as many as 58.3% LAPC-N-S patients achieved grade 3 (<10% viable tumor cells) histology responses. Although the R0 resection rates of LAPC-N-S and LAPC-S were similar (78.6% vs. 73.7%), mFOLFIRINOX-based NAT maintained surgical safety. LAPC-S patients suffered longer operation time, more blood transfusion, and higher prevalence of complications. Two (12.5%) cases of grade 5 complication were observed in the LAPC-S group, and three (15.8%) patients died within 90 days after surgery.
Survival was also evaluated (patients who were lost to follow-up or who had grade 5 complications were excluded; Fig. 1 ). The median OS and PFS of LAPC-N-S patients were 27.7 months and 19.3 months, respectively, which were similar to those of patients with RPC (30.0 months and 23.0 months) and were significantly longer than those of LAPC-S patients (8.9 months and 7.6 months). Patient selection and downstaging through preoperative treatment were the reasons for better outcomes. However, NAT did not reduce the risk of local or distal recurrence of patients with LAPC undergoing tumor resection in local or distal disease. The survival of LAPC-S patients was even poorer than that of LAPC-N patients without surgery (13.2 months and 11.9 months). Surgical complications or injury and irregular or delayed adjuvant therapy may be the causes of compromised survival. Regular and effective systemic treatment, including NAT and adjuvant therapy, is strongly recommended for all patients with LAPC. Progression-free survival Figure 1 . Overall survival and progression-free survival of patients with pancreatic cancer. The overall survival and progression survival of LAPC patients with neoadjuvant therapy (LAPC-N) (A). The overall survival and progression survival of LAPC-N patients with surgical resection (LAPC-N-S) and LAPC-N patients with nonsurgical treatment (LAPC-N-NS) (B and C). Two patients were considered surgically unresectable intraoperatively, and they were not included in survival analysis of subgroups of LAPC-N with tumor resection and LAPC-N without surgical treatment. Abbreviations: LAPC, locally advanced pancreatic cancer; LAPC-N, LAPC with neoadjuvant therapy; LAPC-N-S, LAPC-N with surgical resection; LAPC-S, LAPC with upfront surgery; LAPC-NS, LAPC-N with nonsurgical treatment; RPC, resectable pancreatic cancer. Response Assessment PR n = 13 (37.1%)
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Response Assessment SD n = 14 (40.0%)
Response Assessment PD n = 8 (22.9%)
Response Assessment OTHER n = 0 (0%) (Median) Duration Assessments PFS 13.0 months (Median) Duration Assessments OS 19.6 months Outcome Notes A total of 41 patients were enrolled, and the number of patients who presented with complete response, partial response, stable disease, and progressive disease after NAT treatment was 0, 13, 14, and 8, respectively (35 in total). We did not evaluate the treatment response of the other six patients, because they received fewer than four cycles of mFOLFIRINOX treatment (response was evaluated after a patient finished at least four cycles of treatment). Hence, these six patients were not included in further evaluation for efficacy, and the objective response rate was 37.1% (13/35). These six patients did not undergo surgical treatment; however, they were included in the survival analysis of LAPC-N groups that did and did not undergo surgery. 81  17  2  0  0  0  19  Febrile neutropenia  98  0  0  2  0  0  2  Infections and infestations  90  5  5  0  0  0  10  Anemia  22  5  51  22  0  0  78  Platelet count decreased  73  10  5  12  0  0  27  Neutrophil count decreased  37  5  34  22  2  0  63 Abbreviation: NC/NA, no change from baseline/no adverse event.
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Active and should be pursued further Pancreatic cancer is a malignant disease with an extremely poor prognosis [1] , largely because only 15%-20% of patients are eligible for potentially curative surgery at diagnosis [2] . Systemic therapy is required for pancreatic cancer in all stages, and surgery is the only approach to significantly improve survival and outcomes [3] . Neoadjuvant therapy (NAT) may be recommended for patients with locally advanced pancreatic cancer (LAPC) [4, 5] , and FOLFIRINOX regimens are first-line neoadjuvant chemotherapies for LAPC worldwide [6] . However, the promotion of NAT for Chinese patients with LAPC has been a challenge.
Recently, modification of FOLFIRINOX have been adopted worldwide by omitting bolus 5-FU and decreasing the dose of irinotecan [7] [8] [9] . Based on the published data, we further reduced oxaliplatin to 80% of the full dose. We used a further modified FOLFIRINOX (mFOLFIRINOX) regimen (oxaliplatin 68 mg/m 2 , leucovorin 400 mg/m 2 , irinotecan 135 mg/m 2 , and fluorouracil 2,400 mg/m 2 ) in patients with metastatic pancreatic cancer and obtained promising results [10] , suggesting that mFOLFIRINOX may be useful in patients with LAPC. Hence, we adopted the mFOLFIRINOX regimen in patients with LAPC to evaluate surgical resectability, surgical morbidity and mortality, and long-term survival.
Forty-one patients with LAPC were enrolled as a prospective cohort and received NAT with mFOLFIRINOX from April 2014 to November 2017 in our institution. Patients who were histologically confirmed as pancreatic adenocarcinoma and diagnosed as LAPC by a multidisciplinary team according to the National Comprehensive Cancer Network definitions were eligible for inclusion. Exclusion criteria were (a) Eastern Cooperative Oncology Group performance score higher than 2; (b) inadequate bone marrow, liver or renal function; (c) with additional malignancies; (d) more than 80 years of age. Moreover, data from 74 patients with resectable pancreatic cancer (RPC; from April 2012 to November 2017) and 19 patients with LAPC with upfront surgery (LAPC-S; from April 2012 to March 2014) were collected retrospectively, forming two retrospective, observational cohorts that served as benchmarks to evaluate the treatment outcome of patients with LAPC with neoadjuvant mFOLFIRINOX.
A phase II trial conducted by Conroy et al. was the first to demonstrate the effectiveness of FOLFIRINOX in LAPC [11] . Moreover, the overall response rate was 26% with progression-free survival (PFS) and overall survival (OS) of 7.6 months and 15.7 months, respectively [11] . Confirmatory studies found a comparable response rate of 30% with median OS of 15.7-26 months [7, 12, 13] . In our study, 41 patients received mFOLFIRINOX-based NAT, and 35 of them were restaged after treatment. The prevalence of a relative response and disease control was 37.1% and 77.1%, respectively, which was similar to the data obtained from the studies mentioned above. A median OS of 19.6 months was obtained in the entire group of patients with LAPC with mFOLFIRINOX-based NAT (LAPC-N). Our modification did not appear to attenuate the efficacy of full-dose FOLFIRINOX; however, this would need to be assessed by a prospective randomized study.
During treatment, the most common grade 3 or 4 adverse effects reported by Suker et al. in a metaanalysis of 490 patients with LAPC were neutropenia (27%), fatigue (14%), diarrhea (10%), and vomiting (8%) [14] . Using our dose-modified FOLFIRINOX regimen, the prevalence of neutropenia was reduced to 24.4%. No grade 3 or 4 fatigue, diarrhea, or vomiting were observed. However, our cohort experienced a higher prevalence of anemia (22.0%) and thrombocytopenia (12.2%) despite the use of granulocyte colony-stimulating factor, interleukin-11, or thrombopoietin during treatment. Hence, our modification resulted in better safety and tolerability. However, more attention should be given to hematologic adverse events during mFOLFIRINOX use.
According to recent research, NAT can result in better surgical resectability in patients with LAPC after downstaging [11, 15, 16] . Fourteen patients with LAPC-N underwent surgery in our study (LAPC-N-S), and the rate of conversional surgery achieved 34.1%, which was similar to that of patients with LAPC with modified or full-dose FOLFIRINOX regimens [14] . NAT contributed to a remarkable decrease in CA19-9 level and tumor diameter, but vascular involvement persisted, findings that are similar to those of Donahue et al. [17] . The imaging evidence of changes in vascular involvement is not considered an essential criterion for conversion to surgery [17] . We set these retrospective observational cohorts of RPC and LAPC-S as control groups to evaluate the differences regarding surgical resectability and safety. Unexpectedly, we did not observe improved surgical resectability in the LAPC-N group compared with that in LAPC-S cases (R0: 78.6% vs. 73.7%). Also, 15.8% of LAPC-S and 14.3% of LAPC-N-S patients continued to have surgically unresectable tumors intraoperatively. To achieve complete resection, a much more aggressive approach was needed, so total pancreatectomy was done in 25.0% of LAPC-S patients. As a result, LAPC-S patients suffered a longer operative time and greater blood loss compared with LAPC-N-S patients. Moreover, two LAPC-S patients suffered a grade 5 complication after surgery. Hence, patients with LAPC could benefit from NAT with regard to surgical safety.
According to our data, patients with LAPC without NAT were more likely to exhibit advanced pathologic staging at surgery than those in the LAPC-N-S group (IIb: 43.8% vs. 8.3%; III: 37.5% vs. 25.0%), which was strongly correlated with poor survival. NAT contributed to a significantly reduced prevalence of lymph-node positivity in LAPC-N cases and achieved a grade 3 pathologic response of 58.3%. Investigators have reported that patients with negative lymph nodes and pathologic response have better outcomes [18, 19] .
We further analyzed perioperative complications and survival in cohorts of RPC, LAPC-S, and LAPC-N-S cases. LAPC-N-S patients suffered a higher risk of pancreatic fistulae than that of LAPC-S. The difference in the prevalence of pancreatic fistulae could partially be because four LAPC-S patients underwent total pancreatectomy. The prevalence of grade 2 or 3 complications was otherwise similar between LAPC-S and LAPC-N-S patients. Two LAPC-N-S patients and one LAPC-S patient underwent unplanned reoperation. LAPC-N patients may be at a higher risk of perioperative complications because of the increased complexity of surgery caused by NAT and NAT-related toxicity [20] .
The contribution of NAT to survival in patients with LAPC was also evaluated. The median OS and PFS of 12 LAPC-N-S patients with tumor resection were 27.7 months and 19.3 months, respectively. Also, 27 LAPC-N patients who did not undergo surgery (LAPC-N-NS) had a median OS and PFS of 13.2 months and 11.9 months.
Interestingly, the median OS of LAPC-N-S patients was similar to that of patients with RPC (27.7 m vs. 30.0 m). Patient selection and downstaging through NAT may be reasons for better outcomes. However, NAT did not reduce the prevalence of recurrence of patients with LAPC undergoing tumor resection in local or distal disease. The median OS and PFS of LAPC-S patients was limited to 8.9 m and 7.6 m, respectively, which was shorter than those of LAPC-N-NS patients. Irregular adjuvant therapy may be the main reason for compromised survival. Only 43.8% of LAPC-S patients received chemotherapy postoperatively, whereas the prevalence was 66.2% for patients with RPC and 83.3% for LAPC-N-S patients. Moreover, 85.7% of LAPC-S patients underwent gemcitabine therapy, which is not as intense as that of mFOLFIRINOX or nab-paclitaxel plus gemcitabine [15] . Compared with LAPC-S patients, LAPC-N-NS patients underwent continuous treatment with mFOLFIRINOX or nab-paclitaxel plus gemcitabine, and they did not have surgical complications or injury. Taken together, LAPC-N-NS patients showed longer survival than LAPC-S patients. 
